ResourcePath’s Mission
At ResourcePath, our mission is to bridge the gap between groundbreaking research and clinical diagnostics. We recognize that researchers need to focus their brilliance on innovation and discovery, while clinical labs often lack the agility to bring innovations to patients quickly. That’s where we come in. With our expertise in translating research into actionable diagnostics, we specialize in delivering rapid, reliable tests for rare and emerging diseases, ensuring life-changing diagnostics reach patients who need them most.
- Translational Research: Focused on bringing diagnostics from the bench to bedside, particularly in oncology, infectious disease, and microbiology.
- Cancer Diagnostics: Expertise in ctDNA biomarker assays for DICER1 related tumors and Diffuse Midline Glioma, large sequencing panels for oncogenes, and expression analysis .
- Infectious Diseases: Worked with partners to develop PCR diagnostics for Zika, COVID-19, Flu, RSV, and microbiome research.
- Collaborations: Strong partnerships with academic and clinical institutions, including a significant relationship with Rutgers for PCR technology.
- Regulatory Expertise: CLIA-licensed, CAP-accredited, with experience in FDA EUA submission and adept at navigating the regulatory landscape for clinical assays.
- Clinical Trials: Supporting multinational trials and collaborating with NIH (NIAID) on their Pre Clinical Services Program.
- Commercialization: Awarded multiple SBIR grants for the development of assays in oncology, with additional work in progress for long COVID diagnostics.
- DNA and RNA extractions from clinical and research specimens including FFPE tissue; recovery of cell-free DNA from whole blood, plasma or other fluids
- Next-gen RNA-seq for expression profiling
- Targeted next-gen DNA sequencing with your custom panel
- Tumor profiling for oncogene and tumor suppressor mutations, fusions and copy number variations
- Real-time PCR
- Droplet digital PCR assays for quantitative, ultra-sensitive detection of rare variants in high-complexity or heterogeneous samples.
- Multiplex real-time PCR design and validation
- Oncomine Comprehensive Assay v3 (OCAv3)
ResourcePath is a CLIA-certified, CAP-accredited laboratory led by a team of pathologists, public health professionals, and scientists. We specialize in developing and validating diagnostic tests and have deep expertise in molecular diagnostic technologies, including sequencing, PCR, ddPCR, ELISA, and gene expression analysis. Whether it’s pathogen detection or biomarker discovery, we are dedicated to advancing diagnostics and improving patient care through innovative, reliable solutions and partnerships.
What sets us apart
Commitment. We give our patients and clients results they can trust along with a personalized approach to solving their particular clinical or research question. We are a small company who values meeting the unique needs of each patient and/or customer.
ResourcePath is CLIA licensed and CAP accredited. We are accredited by the College of American Pathologists for Anatomic Pathology, Histology and Molecular Diagnostics (CAP#9498234) and licensed by CLIA #49D2118808. Our clinical reports are all reviewed by a Board Certified Pathologist.
We are a local, woman-owned small business serving communities nationwide through cutting edge assay development and scientific research.
We’re research scientists and clinicians. As experienced investigators, we understand the challenges of pushing beyond what’s already known, of seeking out the right tools to make something new and better happen. In addition, we understand the importance of analytical and clinical validation of new tests to ensure confidence in medical decision-making.
ResourcePath is our core lab for pathology and genomics research projects. Whether it’s simply by providing high quality laboratory services or by consulting on project design, funding proposals or regulatory fillings, or by translating your discovery from bench to bedside in our development lab, we’re here to help you answer research questions quickly, expertly, and within budget.
